Our Pricing

Wegovy vs Ozempic Differences: Complete Dose Guide

Published on: June 03, 2026

Understanding wegovy vs ozempic differences uk is essential when considering semaglutide treatment for weight management. Both contain the same active ingredient—semaglutide—but differ significantly in licensed indications, dosing schedules, and clinical outcomes. At Cured Pharmacy, our UK-registered clinical team provides expert guidance to help you access the most appropriate treatment, with Wegovy available from £79.00 following a free online consultation.

What Are Wegovy and Ozempic?

Wegovy and Ozempic are both injectable medications containing semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist licensed by the MHRA for use in the UK [1]. Semaglutide works by mimicking natural gut hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity.

The critical distinction lies in their licensed indications: Ozempic is approved for type 2 diabetes management at doses up to 1 mg weekly, whilst Wegovy is specifically licensed for chronic weight management at higher doses reaching 2.4 mg weekly [1][2]. This difference in maximum dosing reflects the separate clinical trial programmes that established each medication's efficacy for its intended use.

Both medications require subcutaneous injection once weekly and are prescription-only in the UK. A clinical assessment by a UK-registered prescriber is mandatory before either treatment can be dispensed, ensuring the medication is safe and appropriate for your individual circumstances.

Wegovy vs Ozempic Dosing Schedules Compared

Wegovy Dose Escalation

Wegovy follows a structured five-month titration schedule designed to minimise gastrointestinal side effects whilst building to the therapeutic maintenance dose [2]. Patients begin with 0.25 mg weekly for four weeks, then increase to 0.5 mg for four weeks, followed by 1 mg, 1.7 mg, and finally the maintenance dose of 2.4 mg weekly. Each escalation step allows your body to adapt to higher semaglutide levels, reducing the likelihood of nausea and vomiting.

Clinical data from the STEP trials demonstrated that the 2.4 mg maintenance dose produced an average body weight reduction of 14.9% over 68 weeks in participants without diabetes [2]. This higher dose is what differentiates Wegovy's weight management efficacy from lower-dose semaglutide formulations.

Key Differences Between Wegovy and Ozempic

The wegovy vs ozempic differences uk extend beyond just dosing. Wegovy pens are colour-coded by dose strength and designed for the specific titration schedule required for weight management. Ozempic pens contain different dose configurations suited to diabetes treatment protocols.

From a clinical outcomes perspective, the higher 2.4 mg dose in Wegovy consistently produces greater weight reduction than the 1 mg dose typically used in Ozempic [2][4]. In head-to-head comparisons within clinical trials, participants receiving 2.4 mg semaglutide lost significantly more body weight than those on lower doses, demonstrating a clear dose-response relationship.

Licensed Indications and Clinical Use

Ozempic holds UK marketing authorisation exclusively for type 2 diabetes management, with prescribing guidelines focused on glycaemic control and cardiovascular risk reduction in diabetic patients [3]. Its maximum licensed dose of 1 mg weekly reflects the dose required to achieve HbA1c targets in this population.

Wegovy, by contrast, is licensed specifically for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity such as hypertension or dyslipidaemia [2]. Prescribing Ozempic off-licence for weight loss is not supported by UK regulatory guidance and may not provide the full therapeutic benefit demonstrated in weight management trials.

Wegovy or Ozempic for Weight Loss: Clinical Evidence

When evaluating wegovy or ozempic for weight loss, the clinical trial data strongly supports Wegovy as the appropriate choice. The STEP programme—a series of randomised controlled trials involving over 4,500 participants—established semaglutide 2.4 mg as a highly effective weight management intervention [2][4].

In the pivotal STEP 1 trial, participants receiving Wegovy 2.4 mg achieved an average weight loss of 14.9% from baseline over 68 weeks, compared to 2.4% in the placebo group [2]. Importantly, 86.4% of Wegovy participants achieved at least 5% weight loss—the threshold associated with clinically meaningful health improvements—and 69.1% achieved at least 10% weight loss.

Whilst Ozempic has demonstrated modest weight loss as a secondary outcome in diabetes trials, these studies used lower doses (0.5 mg and 1 mg) and enrolled different patient populations [3]. The weight reductions observed with Ozempic 1 mg, whilst clinically significant for diabetic patients, do not match the magnitude of loss seen with Wegovy's 2.4 mg dose in dedicated obesity trials [4].

Your UK prescriber will assess your medical history, current medications, and weight management goals to determine whether Wegovy is appropriate for you. Factors such as previous weight loss attempts, obesity-related complications, and contraindications all influence treatment selection.

Side Effects and Safety Considerations

Serious adverse effects are rare but include potential risks of pancreatitis, gallbladder disease, and hypoglycaemia (particularly when used alongside other glucose-lowering medications) [1][2]. Semaglutide carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans. Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Regular monitoring by your prescriber is essential throughout treatment. At Cured Pharmacy, our clinical team provides ongoing support and can adjust your treatment plan if side effects become troublesome or if dose modification is required for safety reasons.

Common Adverse Effects

Both Wegovy and Ozempic share a similar side effect profile, as they contain the same active ingredient [1][2]. The most frequently reported adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These symptoms are typically most pronounced during dose escalation and tend to diminish over time as your body adapts.

In the STEP trials, approximately 44% of Wegovy participants experienced nausea, compared to 17% in the placebo group, though most cases were mild to moderate in severity [2]. The gradual dose titration schedule is specifically designed to minimise these effects whilst building to the therapeutic dose.

Accessing Wegovy Through Cured Pharmacy

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all clinical services to ensure the highest standards of pharmaceutical care. Every prescription medication we dispense is genuine and UK-licensed, sourced directly from authorised wholesalers.

Ongoing support is available throughout your treatment journey. If you experience side effects, have questions about dose escalation, or need guidance on injection technique, our clinical team is accessible by phone at (+44) 116 4646009. We're committed to helping you achieve your weight management goals safely and effectively under proper medical supervision.

Simple Online Assessment Process

Getting started with Wegovy at Cured Pharmacy takes under three minutes. Our online clinical assessment is reviewed by UK-registered prescribers who evaluate your medical history, current medications, and suitability for semaglutide treatment. If approved, your prescription is issued electronically and dispensed by our GPhC-registered pharmacy (registration number 9012511).

We offer transparent upfront pricing with Wegovy available from £79.00, significantly lower than typical market rates. Your medication is dispatched in 100% discreet packaging with tracked delivery, ensuring privacy and reliability throughout the process.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Ozempic, Wegovy): Summary of Product Characteristics. GOV.UK. [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141 [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy and Ozempic are prescription-only medicines containing semaglutide. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, diet, and physical activity. Side effects may occur; refer to the Patient Information Leaflet or consult your prescriber for full safety information.